Combined Application of CEA, CA 15-3, and CA 27-29 for the Evaluation of Diagnostic Performance in Canine Mammary Gland Tumors
10.17555/jvc.2024.41.6.359
- Author:
Seung-Hyun KIM
1
;
Dae Sung YOO
;
Dae-Hun PARK
;
Seung-Sik CHO
;
Seungjo PARK
;
Bock-Gie JUNG
;
Sang-Ik PARK
;
Chun-Sik BAE
Author Information
1. Department of Veterinary Surgery, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Korea
- Publication Type:Original Article
- From:
Journal of Veterinary Clinics
2024;41(6):359-369
- CountryRepublic of Korea
- Language:English
-
Abstract:
Canine mammary gland tumors (MGTs) pose a significant challenge due to their malignancy and the burden they place on the affected animals. Recent studies on human breast cancer have explored the potential of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 15-3, and cancer antigen (CA) 27-29, which originate from the mammary gland or somewhere else, as an area of interest for early tumor detection. The use of ELISA measurements of CEA, CA 15-3, and CA 27-29 has shown promising diagnostic performance in detecting canine MGTs. Elevated levels of CEA were observed in both MGT and ovarian cancer patients, while increased levels of CA 15-3 and CA 27-29 were found only in MGT patients. This indicates that the combined use of these biomarkers through ELISA testing can effectively differentiate MGT from other tumors and may be useful in monitoring metastasis and recurrence of canine MGT. In terms of sensitivity and specificity, only CA 27-29 exhibited significant diagnostic performance in detecting and distinguishing MGT from other cancers. This underscores the need for further research to evaluate the diagnostic performance of CEA and CA 15-3 using a larger sample size. Considering the potential overlap of biomarkers associated with specific tumors in different organs, the combined application of tumor markers is crucial to enhance the sensitivity and specificity of cancer diagnosis. Therefore, this study underscores the potential use of combined biomarkers in veterinary medicine, aligning with the recent progress in the exploration of blood biomarkers in human oncology.
